Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19071109 | COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF | March 2025 | December 2025 | Allow | 9 | 2 | 0 | No | No |
| 19005623 | COMPOSITIONS COMPRISING PEMVIDUTIDE AND AN ACYLATED AMINO ACID | December 2024 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18604387 | NUCLEASE-DENDRIMER FORMULATIONS FOR COVID-19 AND BROAD-SPECTRUM ANTIVIRAL THERAPY AND PROPHYLAXIS | March 2024 | October 2025 | Allow | 19 | 0 | 1 | No | No |
| 18374478 | H-NOX PROTEINS FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS | September 2023 | October 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18463221 | USE OF ANTI-AGING GLYCOPEPTIDES TO ENHANCE PANCREATIC CELL HEALTH, SURVIVAL AND IMPROVE TRANSPLANT OUTCOME | September 2023 | September 2025 | Allow | 24 | 2 | 0 | No | No |
| 18298209 | ANTIMICROBIAL PEPTIDE (AMP) FOR CONTROLLING PSEUDOMONAS SYRINGAE PV. ACTINIDIAE (PSA) AND PREPARATION METHOD AND USE THEREOF | April 2023 | September 2025 | Allow | 29 | 2 | 0 | Yes | No |
| 18177367 | De Novo Design of Immunoglobulin-like Domains | March 2023 | August 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18150761 | RECOMBINANT FACTOR VIII VARIANTS | January 2023 | August 2025 | Abandon | 31 | 0 | 1 | No | No |
| 18064571 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME | December 2022 | October 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18057567 | Targeted Therapy of Kidney Fibrosis | November 2022 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 18055255 | MULTIMERIC BICYCLIC PEPTIDE LIGANDS | November 2022 | March 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17915847 | EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING COVID-19 | September 2022 | January 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17905010 | PBP3 BINDING BICYCLIC PEPTIDE LIGANDS | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17820251 | GLP-1 AGONIST POLYPEPTIDE COMPOUND AND SALT THEREOF, SYNTHESIS METHOD THEREFOR AND USE THEREOF | August 2022 | November 2025 | Allow | 39 | 1 | 1 | No | No |
| 17757622 | PCSK9 ANTAGONIST COMPOUNDS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17785758 | INCRETIN ANALOGS AND USES THEREOF | June 2022 | May 2025 | Allow | 35 | 0 | 0 | No | No |
| 17782935 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17781947 | PEPTIDES FOR THE TREATMENT OF CANCER AND/OR METASTASIS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17827055 | CELL PENETRATING PEPTIDES AND USES THEREOF | May 2022 | November 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17777917 | IMMUNOMODULATORS | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17733886 | NUTRITIONALLY-OPTIMIZED COLLAGEN PEPTIDE | April 2022 | September 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17769668 | BICYCLIC PEPTIDE LIGAND DRUG CONJUGATES | April 2022 | March 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17768199 | Proteasome Inhibitors | April 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17648560 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | January 2022 | March 2024 | Allow | 26 | 2 | 0 | No | No |
| 17617670 | PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONIST | December 2021 | November 2025 | Allow | 47 | 2 | 0 | No | No |
| 17613272 | CYCLIC DOMINANT NEGATIVE COMPETENCE STIMULATING PEPTIDE ANALOGS AND METHODS OF TREATING STREPTOCOCCUS PNEUMONIAE INFECTIONS | November 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17444294 | NOVEL LINKERS | August 2021 | October 2025 | Allow | 50 | 1 | 1 | No | No |
| 17310431 | PHARMACEUTICAL TACI-FC FUSION PROTEIN FORMULATION | August 2021 | August 2025 | Allow | 49 | 1 | 1 | No | No |
| 17311062 | LINKERS | June 2021 | August 2025 | Allow | 51 | 2 | 1 | No | No |
| 17299292 | POLYPEPTIDE HAVING EFFECT OF INHIBITING PROLIFERATION OF LEUKEMIA CELLS | June 2021 | June 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17186489 | Enhancers of Neurolysin Activity | February 2021 | February 2025 | Allow | 47 | 1 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner BOWLES, DAVID PAUL works in Art Unit 1654 and has examined 7 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner BOWLES, DAVID PAUL's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by BOWLES, DAVID PAUL receive 1.29 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by BOWLES, DAVID PAUL is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by BOWLES, DAVID PAUL. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.